Transactivation via the human glucocorticoid and mineralocorticoid receptor by therapeutically used steroids in CV-1 cells: a comparison of their glucocorticoid and mineralocorticoid properties
The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Glucocorticoids (GCs) are commonly used for long-term medication in immunosuppressive and anti-inflammatory therapy. However, the data describing gluco- and mineralo-corticoid (MC) properties of widely applied synthetic GCs are often based on diverse clinical observations and on a variety of in vitro tests under various conditions, which makes a quantitative comparison questionable. METHOD: We compared MC and GC properties of different steroids, often used in clinical practice, in the same in vitro test system (luciferase transactivation assay in CV-1 cells transfected with either hMR or hGRalpha expression vectors) complemented by a system to test the steroid binding affinities at the hMR (protein expression in T7-coupled rabbit reticulocyte lysate). RESULTS AND CONCLUSIONS: While the potency of a GC is increased by an 11-hydroxy group, both its potency and its selectivity are increased by the Delta1-dehydro-configuration and a hydrophobic residue in position 16 (16-methylene, 16alpha-methyl or 16beta-methyl group). Almost ideal GCs in terms of missing MC effects, as defined by our in vitro assay, are therefore prednylidene, budesonide, beclomethasone and betamethasone.The MC potency of a steroid is increased by a 9alpha- or a 6alpha-fluoro substituent. A hydrophilic substituent in position 16 (like 16-hydroxylation in triamcinolone) decreases both MC and GC properties. As no substituent that leads to an isolated reduction of GC activity could be characterized in our experiments, 9alpha-fluorocortisol, the most frequently used steroid for MC substitution, seems to be the best choice of available steroids for this purpose.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Previous studies on negative feedback in humans have predominately used the potent GC agonist dexamethasone to inhibit the HPA axis activity over long time: in the clinical practice, this mechanism is used to confirm the diagnosis of Cushing’s syndrome, characterized by the loss of the capacity of response of HPA axis to GC feedback [65].”
From Treatment with synthetic glucocorticoids and the hypothalamus-pituitary-adrenal axis (2017) · cites this paper as [65]
In the citing paper
“Previous studies on negative feedback in humans have predominately used the potent GC agonist dexamethasone to inhibit the HPA axis activity over long time: in the clinical practice, this mechanism is used to confirm the diagnosis of Cushing’s syndrome, characterized by the loss of the capacity of response of HPA axis to GC feedback [65].”
From Treatment with synthetic glucocorticoids and the hypothalamus-pituitary-adrenal axis (2017) · cites this paper as [65]
In the citing paper
“Previous studies on negative feedback in humans have predominately used the potent GC agonist dexamethasone to inhibit the HPA axis activity over long time: in the clinical practice, this mechanism is used to confirm the diagnosis of Cushing’s syndrome, characterized by the loss of the capacity of response of HPA axis to GC feedback [65].”
From Treatment with synthetic glucocorticoids and the hypothalamus-pituitary-adrenal axis (2017) · cites this paper as [65]
In the citing paper
“For example, regarding triamcinolone, its relatively low receptor affinity, both for MRs and GRs, contrasts with its high in vivo potency [65].”
From Treatment with synthetic glucocorticoids and the hypothalamus-pituitary-adrenal axis (2017) · cites this paper as [65]
In the citing paper
“Furthermore, the presence of the 6α-methyl group diminishes the MC activity in vivo, as shown for 6α-methylprednisolone, which presents lower MC activity, but higher GC activity compared with prednisolone [65].”
From Treatment with synthetic glucocorticoids and the hypothalamus-pituitary-adrenal axis (2017) · cites this paper as [65]
10 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
The Steroid and Thyroid Hormone Receptor Superfamily
Evans, R. M. (1988) · Science · doi:10.1126/science.3283939 · Cited by 7,439
Arriza, J. L., Weinberger, C., Cerelli, G., Glaser, T. M., Handelin, B. L., Housman, D. E., & Evans, R. M. (1987) · Science · doi:10.1126/science.3037703 · Cited by 1,946
Steroid Receptor Interactions with Heat Shock Protein and Immunophilin Chaperones*
Pratt, W. B., & Toft, D. O. (1997) · Endocrine Reviews · doi:10.1210/edrv.18.3.0303 · Cited by 1,791
Functional domains of the human glucocorticoid receptor
Giguère, V., Hollenberg, S. M., Rosenfeld, M. G., & Evans, R. M. (1986) · Cell · doi:10.1016/0092-8674(86)90339-9 · Cited by 918
Differential Recognition of Target Genes by Nuclear Receptor Monomers, Dimers, and Heterodimers*
GLASS, C. K. (1994) · Endocrine Reviews · doi:10.1210/edrv-15-3-391 · Cited by 829
Bledsoe, R. K., Montana, V. G., Stanley, T. B., Delves, C. J., Apolito, C. J., McKee, D. D., Consler, T. G., Parks, D. J., Stewart, E. L., Willson, T. M., et al. (2002) · Cell · doi:10.1016/s0092-8674(02)00817-6 · Cited by 818 · cited 1×
“Comparing the influence of further functional groups on transactivation via the hGR and the hMR will help to understand the structure ( 52 , 53) and functionality of the substrate binding sites in these receptors.”
BackgroundChandler, V. L., Maler, B. A., & Yamamoto, K. R. (1983) · Cell · doi:10.1016/0092-8674(83)90430-0 · Cited by 667
Podolsky, D. K. (1991) · New England Journal of Medicine · doi:10.1056/nejm199110033251406 · Cited by 541
Repression of inflammatory responses in the absence of DNA binding by the glucocorticoid receptor
Reichardt, H. M. (2001) · The EMBO Journal · doi:10.1093/emboj/20.24.7168 · Cited by 429
Transcriptional cross-talk, the second mode of steroid hormone receptor action
Göttlicher, M., Heck, S., & Herrlich, P. (1998) · Journal of Molecular Medicine · doi:10.1007/s001090050242 · Cited by 388
Cited by
Items 101–200 of 212
Zola, M., Mejlachowicz, D., Gregorio, R., Naud, M., Jaisser, F., Zhao, M., & Béhar‐Cohen, F. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031278 · Cited by 22
Chadwick, J. A., Hauck, J. S., Gómez-Sánchez, C. E., Gómez-Sánchez, E. P., & Rafael‐Fortney, J. A. (2017) · Physiological Genomics · doi:10.1152/physiolgenomics.00128.2016 · Cited by 27
Lambert, K. G., Hunter, R. G., Bartlett, A. A., Lapp, H. E., & Kent, M. (2019) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2019.100802 · Cited by 23
de Lima, L. A. C. V., & Nascimento, A. S. (2012) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2012.11.013 · Cited by 29
Longui, C. A., Santos, M. C., Formiga, C. B., Oliveira, D. V. A., Rocha, M. N., Faria, C. D. C., Kochi, C., & Monte, O. (2005) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302005000300008 · Cited by 24
“Cortisol and a variety of synthetic glucocorticoid agonists are able to control carbohydrate, protein and lipid metabolism, and to regulate immune and cardiovascular functions (1,2).”
BackgroundIbrahim, S. I. A., Xie, W., Strong, J. A., Tonello, R., Berta, T., & Zhang, J. (2018) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2018.00453 · Cited by 21
Cuffini, S. L., Ellena, J., Mascarenhas, Y. P., Ayala, A. P., Sielser, H. W., Filho, J. M., Monti, G. A., Aiassa, V., & Sperandeo, N. R. (2007) · Steroids · doi:10.1016/j.steroids.2006.11.020 · Cited by 21
Nethathe, G. D., Lipman, J., Anderson, R., Fuller, P. J., & Feldman, C. H. (2023) · British Journal of Anaesthesia · doi:10.1016/j.bja.2023.10.034 · Cited by 27
“41,42 However, although fludrocor-tisone is a potent glucocorticoid, 41 its effects are largely mineralocorticoid at the low dosage used because of its significantly greater potency at the MR. Additionally, various genomic and non-genomic effects of fludrocortisone, and a yet unidentified mechanism…”
BackgroundStewart, P. M., & Newell-Price, J. D. C. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-29738-7.00015-0 · Cited by 35
Thiesson, H. C., Jensen, B. L., Bistrup, C., Ottosen, P. D., McNeilly, A. D., Andrew, R., Seckl, J. R., & Skøtt, O. (2006) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00418.2005 · Cited by 23
“Dexamethasone binds to the MR in vitro with an affinity close to that of glucocorticoids (20), suggesting that dexamethasone could act as a MR antagonist.”
BackgroundDoes mineralocorticoid receptor play a vital role in the development of depressive disorder?
Chen, J., Wang, Z., Zhang, S., Zuo, W., & Chen, N. (2016) · Life Sciences · doi:10.1016/j.lfs.2016.03.022 · Cited by 21
“Moreover, the affinity of the endogenous hormones corticosterone and cortisol for MR is approximately 10-fold higher than the affinity for GR (Grossmann et al., 2004).”
BackgroundLiebau, A., Pogorzelski, O., Salt, A. N., & Plontke, S. K. (2018) · Otology & Neurotology · doi:10.1097/mao.0000000000001872 · Cited by 27
Chen, J., Wang, Z., Zhang, S., Chu, S., Mou, Z., & Chen, N. (2019) · Behavioural Brain Research · doi:10.1016/j.bbr.2019.01.026 · Cited by 23
“On the other hand, the low level of glucocorticoids in the ADX rats could not fully activate the MR since a high MR occupancy could be observed under basal conditions [50], thus the MR signal was also absent in the ADX rats (treated with low level of corticosterone) under stress.”
Dexamethasone stimulates endothelin-1 gene expression in renal collecting duct cells
Stow, L. R., Voren, G., Gumz, M. L., Wingo, C. S., & Cain, B. D. (2011) · Steroids · doi:10.1016/j.steroids.2011.12.011 · Cited by 16
“Aldosterone is not a substrate for this enzyme, so 11βHSD-2 acts only on endogenous glucocorticoids, such as cortisol, producing 11-keto metabolites that do not activate MR or GR [13, 14].”
BackgroundCardiac Function in Congenital Adrenal Hyperplasia: A Pattern of Reversible Cardiomyopathy
Minette, M. S., Hoyer, A. W., Pham, P. P., DeBoer, M. D., Reller, M. D., & Boston, B. A. (2013) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2012.11.086 · Cited by 17
Zubiría, M. G., Giordano, A. P., Gambaro, S. E., Alzamendi, A., Frontini-López, Y. R., Moreno, G., Spinedi, E., & Giovambattista, A. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118363 · Cited by 20
Tschaidse, L., Reisch, N., Arlt, W., de la Perrière, A. B., Hirschberg, A. L., Juul, A., Mallappa, A., Merke, D. P., Newell-Price, J. D. C., Perry, C. G., et al. (2023) · European Journal of Endocrinology · doi:10.1093/ejendo/lvac006 · Cited by 16
Ito‐Harashima, S., Shiizaki, K., Kawanishi, M., Kakiuchi, K., Onishi, K., Yamaji, R., & Yagi, T. (2015) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2015.06.001 · Cited by 15
Development and Validation of a Dissolution Test for 6 mg Deflazacort Tablets
Sperandeo, N. R., & Kassuha, D. (2009) · Scientia Pharmaceutica · doi:10.3797/scipharm.090405 · Cited by 17
“It is a poorly water-soluble compound [4] with an oral bioavailability of about 70 %, which exhibits low mineralocorticoid activity [5] and was promoted as a relatively bone-sparing glucocorticoid when compared with other glucocorticoids [2, 6, 7].”
BackgroundSpiga, F., Harrison, L. R., Wood, S. A., MacSweeney, C. P., Thomson, F. J., Craighead, M., Grassie, M., & Lightman, S. L. (2008) · Journal of Endocrinology · doi:10.1677/joe-07-0503 · Cited by 15
“MPL is a synthetic glucocorticoid that binds to both GR and MR (Grossmann et al. 2004).”
BackgroundThe Adrenal Cortex and Its Disorders
Miller, W. L., Flück, C. E., Breault, D. T., & Feldman, B. J. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-62520-3.00014-2 · Cited by 38
Zhu, C., Gausterer, J. C., Schöpper, H., Nieratschker, M., Saidov, N., Ahmadi, N., Honeder, C., Gabor, F., & Arnoldner, C. (2018) · Audiology and Neurotology · doi:10.1159/000487662 · Cited by 14
“To our knowledge, there are no such data on TAAC, and therefore different mineralocorticoid potencies, which have been described in an in vitro model, could explain the variability in the efficacy of these glucocorticoids [Grossmann et al., 2004].”
BackgroundSynthetic Glucocorticoids and Early Variations of Blood Pressure: A Population-Based Cohort Study
Fardet, L., Nazareth, I., & Petersen, I. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1127 · Cited by 15
“Consequently, mineralocorticoid activity of synthetic glucocorticoids appears to be three to 50 times lower than that of the natural hormone, cortisol (8).”
BackgroundXiao, X., Li, H., Yang, J., Qi, X., Zu, X., Yang, J. L., Zhong, J., Cao, R., Liu, J., & Wen, G.-B. (2014) · Steroids · doi:10.1016/j.steroids.2014.03.004 · Cited by 15
Yawno, T., Mortale, M., Sutherland, A. E., Jenkin, G., Wallace, E. M., Walker, D. W., & Miller, S. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.05.031 · Cited by 15
“…catabolism and cessation of normal growth, since this is a time of maximal fetal growth in sheep (Miller et al., 2012), and perhaps reflects the fact that BM is a more potent glucocorticoid receptor agonist compared to other synthetic glucocorticoids, such as dexamethasone (Grossmann et al., 2004).”
BackgroundKaramouzis, I., Berardelli, R., Marinazzo, E., D’Angelo, V., Zinnà, D., Minetto, M. A., Zichi, C., Fussotto, B., Giordano, R., Ghigo, E., et al. (2012) · Pituitary · doi:10.1007/s11102-012-0435-3 · Cited by 14
“In agreement with this hypothesis, ‘‘in vitro’’ published comparative data have shown that fludrocortisone is not a weak GR agonist, but seems to possess a GR potency higher than that of cortisol [9].”
BackgroundFleischer, J., Wingenfeld, K., Kuehl, L. K., Hinkelmann, K., Roepke, S., & Otte, C. (2015) · Stress · doi:10.3109/10253890.2015.1087504 · Cited by 15
“The extent of its glucocorticoid potency ranges from negligible to rather moderate (Grossmann et al., 2004; Miller et al., 2008).”
BackgroundΜacut, D., Antić, I. B., Nestorov, J. M., Topalović, V., Macut, J. B., Panidis, D., Kotlica, B. K., Papadakis, E. P., Matić, G. M., & Milutinović, D. V. (2015) · HORMONES · doi:10.14310/horm.2002.1526 · Cited by 12
Ngaosuwan, K., Johnston, D. G., Godsland, I. F., Cox, J., Majeed, A., Quint, J. K., Oliver, N. S., & Robinson, S. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab347 · Cited by 14
Koning, A.-S. C. A. M., Habets, P. C., Bogaards, M., Kroon, J., van Santen, H. M., de Bont, J. M., & Meijer, O. C. (2022) · Endocrine Connections · doi:10.1530/ec-21-0425 · Cited by 13
“Cortisol also acts via the mineralocorticoid receptor (MR) in many tissues including the brain [6], but synthetic glucocorticoids have clear preference for GR over MR [7].”
Backgroundvan Hulst, A. M., Verwaaijen, E. J., Fiocco, M. F., Pluijm, S. M. F., Grootenhuis, M. A., Pieters, R., van den Akker, E. L. T., & van den Heuvel‐Eibrink, M. M. (2021) · BMC Pediatrics · doi:10.1186/s12887-021-02896-6 · Cited by 12
“Synthetic glucocorticoids mostly have the GR as their therapeutic target: dexamethasone has a high potency to activate GRs, but does not bind MRs [13].”
BackgroundComprehensive assessment of NR ligand polypharmacology by a multiplex reporter NR assay
Medvedev, A. V., Moeser, M., Medvedeva, L., Martsen, E., Granick, A., Raines, L. N., Gorman, K. L., Lin, B., Zeng, M., Houck, K. A., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-07031-8 · Cited by 11
van Hulst, A. M., van den Akker, E. L. T., Verwaaijen, E. J., Fiocco, M. F., Rensen, N., van Litsenburg, R. R. L., Pluijm, S. M. F., Zwaan, C. M., van Santen, H. M., Pieters, R., et al. (2023) · European Journal of Cancer · doi:10.1016/j.ejca.2023.03.039 · Cited by 13
“Dexamethasone has a high affinity for the GR, but in contrast to other glucocorticoids, binds the MR to a minimal extent [8].”
BackgroundGeuens, S., Van Dessel, J., Govaarts, R., Ikelaar, N. A., Meijer, O. C., Kan, H. E., Niks, E. H., Goemans, N., Lemiere, J., Doorenweerd, N., et al. (2023) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51922 · Cited by 11
“52 In addition, daily corticosteroid treatment is expected to chronically suppress cortisol levels, which leads to a chronic inhibition of cortisol-induced natural hormonal processes.”
BackgroundAldosterone Action on Brain and Behavior
Murck, H. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803592-4.00052-3 · Cited by 10
Pomc Knockout Mice Have Secondary Hyperaldosteronism Despite an Absence of Adrenocorticotropin
Linhart, K. B., & Majzoub, J. A. (2007) · Endocrinology · doi:10.1210/en.2006-1136 · Cited by 10
“Dexamethasone was chosen because its glucocorticoid potency is approximately 20-fold greater than that of cortisol, whereas its mineralocorticoid potency is approximately 1% that of aldosterone (23).”
BackgroundOikonomakos, I. T., Arachchige, L. C. W., & Schedl, A. (2021) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2021.111172 · Cited by 12
Preparation and characterization of polymorphs of the glucocorticoid deflazacort
Kassuha, D., Aiassa, V., Bruno, F. P., Cuadra, G. R., & Sperandeo, N. R. (2014) · Pharmaceutical Development and Technology · doi:10.3109/10837450.2013.871033 · Cited by 9
Mineralocorticoid effects in the late gestation ovine fetal lung
McCartney, J., Richards, E. M., Wood, C. E., & KELLER-WOOD, M. E. (2014) · Physiological Reports · doi:10.14814/phy2.12066 · Cited by 8
Mometasone furoate: an inhaled glucocorticoid for the management of asthma in adults and children
Cowie, R. L., Giembycz, M. A., & Leigh, R. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560903078428 · Cited by 9
“The possibility that synthetic glucocorticoids may also be limited in this way leading, potentially, to adverse events should not be understated [14,15].”
BackgroundStaub, Y., Suga, Y., Ikawa, Y., Tsubouchi, K., Mikie, H., Kawagishi, A., Shimada, T., Sai, Y., Nishimura, K., & Matsushita, R. (2019) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155219879992 · Cited by 10
“Meanwhile, DEX does not bind to mineralocorticoid receptors, whereas PSL can activate them weakly.(33) Consequently, the physiological mineralocorticoid effect is reduced by DEX compared with PSL.”
BackgroundMechanisms of ligand-mediated modulation of mineralocorticoid receptor signaling
Fuller, P. J., Yang, J., Young, M. J., & Cole, T. J. (2025) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2025.112504 · Cited by 9
Mineralocorticoid replacement therapy in salt‐wasting congenital adrenal hyperplasia
Lang, K., Quinkler, M. O., & Kienitz, T. (2023) · Clinical Endocrinology · doi:10.1111/cen.14959 · Cited by 9
“53 Consequently, fludrocortisone doses in patients treated with prednisolone may be slightly higher compared to hydrocortisone therapy.”
InfluentialKoning, A.-S. C. A. M., Satoer, D., Vinkers, C. H., Najafabadi, A. H. Z., Biermasz, N. R., Tewarie, R. N., Moojen, W. A., van Rossum, E. F. C., Dirven, C. M. F., Pereira, A. M., et al. (2021) · BMJ Open · doi:10.1136/bmjopen-2021-054405 · Cited by 9
Empiric Determination of the Daily Glucocorticoid Replacement Dose in Adrenal Insufficiency
Caetano, C. M., Śliwińska, A., Madhavan, P., Grady, J. J., & Malchoff, C. D. (2020) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaa145 · Cited by 10
“The HC equivalent of fludrocortisone is reported to be about 10 to 1 [13, 24-26].”
BackgroundManipulating the Brain Corticosteroid Receptor Balance: Focus on Ligands and Modulators
de Kloet, E. R., Zacarías, N. V. O., & Meijer, O. C. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-802175-0.00037-1 · Cited by 10
N-terminal domain influences steroid activation of the Atlantic sea lamprey corticoid receptor
Katsu, Y., Lin, X., Ji, R., Chen, Z., Kamisaka, Y., Bamba, K., & Baker, M. E. (2023) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2023.106249 · Cited by 8
Ahmed, S. E. A. M., Soliman, A. T., Ramadan, M. A. E. F., Elawwa, A., Abugabal, A. M. S., Emam, M. H. A., & Sanctis, V. D. (2019) · Acta bio-medica dell'Ateneo parmense/Acta biomedica · doi:10.23750/abm.v90i3.8732 · Cited by 14
Berardelli, R., Karamouzis, I., D'Angelo, V., Fussotto, B., Minetto, M., Ghigo, E., Giordano, R., & Arvat, E. (2016) · Journal of Endocrinological Investigation · doi:10.1007/s40618-015-0393-5 · Cited by 5
Redon, B., Violleau, C., Georges, F. E., Marsicano, G., & Chaouloff, F. (2019) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2019.104489 · Cited by 7
Wang, H., Kan, W., Feng, Y., Feng, L., Yang, Y., Chen, P., Xu, J.-J., Si, T., Zhang, L., Wang, G., et al. (2021) · World Journal of Psychiatry · doi:10.5498/wjp.v11.i12.1191 · Cited by 5
Diagnosis and management of secondary adrenal crisis
Martel‐Duguech, L., Poirier, J., Bourdeau, I., & Lacroix, A. (2024) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-024-09877-x · Cited by 8
Barroca, N. C. B., Baes, C. V. W., Martins, C. M. S., Bosaipo, N. B., Umeoka, M. S. D. S., Tejada, J., Antunes‐Rodrigues, J., de Castro, M., Juruena, M. F., Garcia‐Cairasco, N., et al. (2020) · eNeuro · doi:10.1523/eneuro.0222-20.2020 · Cited by 5
“It was also used fludrocortisone test, which acts predominantly by binding to MR but part of its action is exerted by binding to the GR (Grossmann et al., 2004; Baes et al., 2014).”
BackgroundMethodLotus birth: asking the next question.
Lim, R. (2001) · PubMed · Cited by 8
Ibrahim, S. I. A., Strong, J., & Zhang, J. (2016) · Journal of Anesthesia and Perioperative Medicine · doi:10.24015/japm.2016.0023 · Cited by 5
“In vitro studies showed that fluticasone activated only the GR, not the MR or other nuclear receptors (48), while 6-α methyl prednisolone, one of the popular steroids used for back pain injections, activated GR and MR with similar potency (38).”
BackgroundUmazume, A., Ohguro, N., Okada, A. A., Namba, K., Sonoda, K., Tsuruga, H., Morita, K., & Gotô, H. (2022) · Japanese Journal of Ophthalmology · doi:10.1007/s10384-022-00923-2 · Cited by 5
“The dose of systemic corticosteroids was converted to a prednisolone equivalent dose by using glucocorticoid potency [28].”
MethodMyint, M., Bucki, R., Janmey, P. A., & Diamond, S. L. (2015) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2015.04.104 · Cited by 4
Qualls, K. A., Kadakia, F. K., Serafin, E. K., Lückemeyer, D. D., Davidson, S., Strong, J. A., & Zhang, J. (2025) · Anesthesia & Analgesia · doi:10.1213/ane.0000000000007133 · Cited by 3
“6,7 Some corticosteroids that are commonly used for ESIs have been shown to have similar (triamcinolone and dexamethasone) or greater (6-α -methylprednisolone) potency in vitro for the MR compared to the GR. 6,8 The MR was first characterized to be widely expressed in sensory neurons of mouse DRGs (mDRGs).”
Auer, M. K., Paizoni, L., Nowotny, H. F., Lottspeich, C., Tschaidse, L., Schmidt, H., Bidlingmaier, M., & Reisch, N. (2023) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2023.106271 · Cited by 3
Beteg, F. I., Lelescu, C. A., Urdă-Cîmpean, A. E., Taulescu, M. A., & Mureșan, C. (2020) · Ankara Üniversitesi Veteriner Fakültesi Dergisi · doi:10.33988/auvfd.724846 · Cited by 3
“TA has a rapid onset of action, prolonged and enhanced anti-inflammatory effect (3–6 weeks or more), decreased mineralocorticoid activity and significant glucocorticoid activity (11, 14).”
BackgroundDevelopmental Consequences of Prenatal Administration of Glucocorticoids in Rodents and Primates
Hauser, J. (2012) · Springer eBooks · doi:10.1007/978-1-4614-5605-6_9 · Cited by 3
Function of human mineralocorticoid receptor splice variant
Bähr, V., Bumke‐Vogt, C., Gotze, J., Pfeiffer, A. F. H., & Diederich, S. (2004) · European Journal of Endocrinology · doi:10.1530/eje.0.1510295 · Cited by 3
Traba, S. A., Bacigalupo, L. D. S., Fradin, D., Talón, I., Heidenreich, A. C., Muraro, D., Garcia‐Bernardo, J., Gribben, C., Lugtu, F., Burgos, J. I., et al. (2025) · Development · doi:10.1242/dev.204361 · Cited by 3
Walther, R., Julius, U., Tselmin, S., Schatz, U., Bornstein, S. R., & Graessler, J. (2019) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2019.08.042 · Cited by 3
Ryckx, S., Schepper, J. D., Giron, P., Maes, K., Vaeyens, F., Wilgenhof, K., Lefesvre, P., Ernst, C. W., Vanderlinden, K., Klink, D. T., et al. (2023) · Journal of Medical Case Reports · doi:10.1186/s13256-023-03889-y · Cited by 3
“However, mineralocorticoid receptor stimulation and subsequent hypertension by adrenal steroids that are not measured routinely cannot be excluded and might be involved in some PASACT cases [38, 39].”
BackgroundKatsu, Y., Zhang, J., & Baker, M. E. (2024) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2024.106548 · Cited by 2
Higgins, Z. R., Garg, S., Burroughs, T. J., Qualls, K. A., Zhang, J., & Strong, J. A. (2024) · Anesthesiology and Perioperative Science · doi:10.1007/s44254-024-00069-z · Cited by 2
“However, in vitro studies show that many clinically used steroids (including those commonly used for back pain, e.g., methylprednisolone and triamcinolone) can also activate the mineralocorticoid receptor (MR) with significant potency [7, 8].”
InfluentialGrzych, H., Fee, E. L., Kemp, M. W., Royse, E. X., Usada, H., Ikeda, H., Takahashi, Y., Takahashi, T., Jobe, A. H., & Hillman, N. H. (2025) · Pediatric Research · doi:10.1038/s41390-025-04172-0 · Cited by 2
“21 Determining corticosteroid regimens that decrease BPD without affecting neurodevelopment is crucial for reducing morbidity in extremely preterm infants.”
Nakajima, K., Ayani, N., Matsuoka, T., Kasahara, K., Nakajima, Y., Ikawa, H., Kitaoka, R., Akimoto, T., & Narumoto, J. (2025) · Psychiatry and Clinical Neurosciences Reports · doi:10.1002/pcn5.70222 · Cited by 2
Cibles rétiniennes d’action des médicaments
Béhar‐Cohen, F. (2011) · Annales Pharmaceutiques Françaises · doi:10.1016/j.pharma.2011.01.003 · Cited by 2
Deflazacort in rheumatology: Where does it stand?
Mohan, M. C., González-Pérez, Ó., Ramos-Remus, C., & Ravindran, V. K. (2014) · Indian Journal of Rheumatology · doi:10.1016/j.injr.2014.09.004 · Cited by 2
Klinge, U., Farman, N., & Fiebeler, A. (2010) · Theoretical Biology and Medical Modelling · doi:10.1186/1742-4682-7-16 · Cited by 2
“1 millimolar - clobetasol(Hd-GC), in 50% ethanol (clobetasol proprionat was purchased from Sigma; it is a widely and topically used glucocorticoid in dermatology, which is a very potent agonist at the glucocorticoid receptor with weak agonistic effects at the mineralocorticoid receptor; see also effects of the compara…”
BackgroundStress en veerkracht: de rol van de mineralocorticoïd receptor
Vinkers, C. H., ter Heegde, F., & Rijk, R. H. D. (2016) · Neuropraxis · doi:10.1007/s12474-016-0116-5 · Cited by 2
Stubsrud, E. (2005) · SUNScholar (Stellenbosch University) · Cited by 2
Díaz, J. I. C., Sieber‐Ruckstuhl, N. S., Boretti, F. S., Fracassi, F., & Reusch, C. E. (2021) · Veterinary Record · doi:10.1002/vetr.242 · Cited by 3
Juruena, M. F., Cleare, A. J., & Young, A. H. (2022) · Neuromethods · doi:10.1007/978-1-0716-2083-0_1 · Cited by 2
Yarushkina, N. I., & Filaretova, L. P. (2023) · Neuroscience and Behavioral Physiology · doi:10.1007/s11055-023-01460-2 · Cited by 1
Is there a role for early postnatal steroids in very preterm infants exposed to chorioamnionitis?
Jain, V. G., & Ambalavanan, N. (2024) · Pediatric Research · doi:10.1038/s41390-024-03031-8 · Cited by 1
Ekman, B., Quinkler, M. O., Zhang, P., Isidori, A. M., Murray, R. D., Wahlberg, J., & on behalf of the EU-AIR investigators (2025) · Journal of Endocrinological Investigation · doi:10.1007/s40618-025-02657-7 · Cited by 2
“Using published data from Grossmann et al. regarding MC potency of various gluco-corticoids [18 ], the combined MC potency of fludrocorti - sone + hydrocortisone-equivalent doses was calculated as described below and in Table 1.”
InfluentialKatsu, Y., Zhang, J., Ao, Y., DONNELLAN, P. S., & Baker, M. E. (2026) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2026.153689 · Cited by 3
Tsiarli, M. A. (2014) · D-Scholarship@Pitt (University of Pittsburgh) · Cited by 1
Mood Disorders and Stress-Related Disorders
Gadelrab, R., & Juruena, M. F. (2024) · Cambridge University Press eBooks · doi:10.1017/9781108973922.011 · Cited by 1
Betamethasone-Associated Psychosis in a Pregnant Woman Diagnosed With Schizophrenia
Spiegel, D. R., Wallace, T., Kozlova, V., Hoff, M., & Benedict, J. (2025) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000002101 · Cited by 1
Steroid Replacement in Adrenal Insufficiency
Blair, J., Debono, M., & Ross, R. J. M. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.64307-6 · Cited by 1
Haine, A. (2011) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-1041
Liposomal targeting of glucocorticoids to inhibit tumor angiogenesis
Banciu, M. (2007) · Utrecht University Repository (Utrecht University)
Brey, D. M. (2010) · ScholarlyCommons (University of Pennsylvania)
Estresse precoce e alterações do eixo hipotálamo-pituitária-adrenal (HPA) na depressão.
Baes, C. V. W. (2012) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.17.2012.tde-30052012-034325 · Cited by 3
Les neutrophiles ne sont pas résistants aux glucocorticoides
Hirsch, G. (2012) · doi:10.71781/3780
A study on the effect of Aldosterone antagonist on Nociception and anxiety in Swiss albino mice
Suresh, M. (2012) · IOSR Journal of Pharmacy (IOSRPHR) · doi:10.9790/3013-0230599603
Khan, A. A. (2014) · Spiral (Imperial College London) · doi:10.25560/29876
Baes, C. V. W. (2016) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.17.2017.tde-27072016-152342 · Cited by 1
Eachus, H., Subramanya, D., Jackson, H. E., Wang, G., Berntsen, K., Ashton, J., Esposito, U., Seifuddin, F., Pirooznia, M., Elhaik, E., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/714873
“…tractability of zebrafish larvae also enabled us to investigate the impacts of exogenous glucocorticoid treatment on DNA methylation and transcription of fkbp5 and aplp1, using the synthetic glucocorticoid betamethasone, which is a selective agonist of the GR (Grossmann et al., 2004).”
(2006) · Current Opinion in Endocrinology & Diabetes · doi:10.1097/01.med.0000202323.44809.4f
Saleem, M. A. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.727847829.793566370
N-terminal Domain Influences Steroid Activation of the Atlantic Sea Lamprey Corticoid ReceptorPreprint
Katsu, Y., Lin, X., Ji, R., Chen, Z., Kamisaka, Y., Bamba, K., & Baker, M. E. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.10.08.511437
Katsu, Y., Lin, X., Ji, R., Chen, Z., Kamisaka, Y., Bamba, K., & Baker, M. E. (2022) · Research Square · doi:10.21203/rs.3.rs-2146191/v1
van Hulst, A. M., van der Zwet, J. C. G., Buijs-Gladdines, J. G. C. A. M., Smits, W. K., Fiocco, M. F., Pieters, R., van Leeuwen, F. N., van den Heuvel‐Eibrink, M. M., van den Akker, E. L. T., & Meijerink, J. P. P. (2024) · Haematologica · doi:10.3324/haematol.2023.282928
Katsu1, Y., Zhang, J., & Baker, M. E. (2024) · Research Square · doi:10.21203/rs.3.rs-4095590/v1
Metadata
- Authors
- Grossmann, C., Scholz, T., Rochel, M., Bumke-Vogt, C., Oelkers, W., Pfeiffer, A., Diederich, S., & Bahr, V
- Affiliations
- Charité – Universitätsmedizin Berlin (DE)
- German Institute of Human Nutrition (DE)
- Venue
- European Journal of Endocrinology
- Publisher
- Oxford University Press (OUP)
- Published
- 2004-09-01
- Volume
- 151
- Issue
- 3
- Pages
- 397-406
- ISSN
- 0804-4643 (ISSN-L)
- 1479-683X
- OpenAlex
- W2102136926
- Cited by
- 212
- References
- 51
- Citations by year
- 2026: 3 · 2025: 8 · 2024: 11 · 2023: 15 · 2022: 12 · 2021: 12 · 2020: 7 · 2019: 17 · 2018: 7 · 2017: 10 · 2016: 13 · 2015: 10 · 2014: 18 · 2013: 5 · 2012: 11
- FWCI
- 2.85
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- European Journal of Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Deutsche Forschungsgemeinschaft
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal Regulation and Hypertension
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Keywords
- glucocorticoid receptor, mineralocorticoid receptor, synthetic glucocorticoids, mineralocorticoid activity, structure-activity relationship, prednisolone, budesonide, beclomethasone, betamethasone, triamcinolone, steroid binding affinity
- MeSH terms
- Animals, Anti-Inflammatory Agents, Cells, Cultured, Chlorocebus aethiops, Dexamethasone, Glucocorticoids, Humans, Hydrocortisone, Kidney, Prednisolone, Pregnadienes, Receptors, Glucocorticoid, Transfection, Receptors, Mineralocorticoid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.